| Literature DB >> 30456580 |
Clemens Steinwender1, Hermann Blessberger2, Daniel Kiblböck2, Karim Saleh2, Jürgen Kammler2.
Abstract
Leadless pacemakers have the potential to fundamentally change the field of device therapy. As leads and generator pockets are no longer needed with this technology, many potentially dangerous complications of conventional pacemaker systems like lead fractures, lead endocarditis or pocket infections can be effectively avoided. At present, Micra™ (Medtronic Inc., Minneapolis, MN, USA) is the only commercially available leadless pacemaker. Since its first-in-human implantation in 2013, thousands of these devices have been implanted worldwide. This article presents an overview of the present clinical evidence and future perspectives of this promising new technology.Entities:
Keywords: Complications; Delivery system; Implantation; Infection; Single chamber pacing
Mesh:
Year: 2018 PMID: 30456580 DOI: 10.1007/s00399-018-0592-9
Source DB: PubMed Journal: Herzschrittmacherther Elektrophysiol ISSN: 0938-7412